Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

July 31, 2013

Conditions

Kidney Diseases

Interventions

DRUG

Molidustat (BAY85-3934)

20 mg molidustat as a single tablet

DRUG

Placebo

Single oral dose of matching placebo will be given in each treatment arm

Trial Locations (3)

Kiel

Mönchengladbach

München